B Cell News and Research

RSS

Substance from pine bark is a potential source for treating melanoma

A substance that comes from pine bark is a potential source for a new treatment of melanoma, according to Penn State College of Medicine researchers.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Studies show mobile phones can cause allergic contact dermatitis in both children and adults

Studies have identified mobile phones and related devices as sources of metal sensitization and potential causes of allergic contact dermatitis (ACD).

21 May 2014

New LASER could revolutionize medicine and our knowledge of the human genome

Within the framework of the European ATLAS project, a team of researchers in Naples has created a LASER-based prototype that could revolutionize medicine and our knowledge of the human genome.

21 May 2014

Space Station science: Microgravity on human thyroid carcinoma cells

The multi-national efforts that go into research aboard the International Space Station show that working together can yield results with universal benefits.

21 May 2014

Pemetrexed plus erlotinib shows benefits in NSCLC

Pemetrexed used in combination with erlotinib may have clinical advantage over single-agent pemetrexed when used as a second-line treatment in patients with non-squamous non-small-cell lung cancer, researchers report.

20 May 2014

Three Chicago-area universities to share research facilities at reduced cost

As research funding from the National Institutes of Health and other federal agencies shrinks, cooperation among Northwestern University, the University of Chicago and the University of Illinois at Chicago is expanding.

20 May 2014

BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for first quarter ended March 31, 2014.

20 May 2014

Existing pharmaceutical drugs may offer effective therapies against MERS

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS).

20 May 2014

Daylight delivers world's first laser-based infrared microscopy platform

Daylight Solutions, Inc., a leading manufacturer of molecular detection and imaging solutions in the mid-infrared, today announced delivery of the world's first commercially available laser-based infrared microscopy platform.

From Daylight Solutions Inc 20 May 2014

Viewpoints: Pence on Medicaid expansion; Jindal on Obamacare repeal efforts; 'long-shot' lawsuits

From the beginning of my tenure as governor in 2013, we have been saying no to Obamacare in Indiana.

20 May 2014

TSRI chemists develop correct structure of highly promising anticancer compound

Chemists at The Scripps Research Institute (TSRI) have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials in cancer patients.

20 May 2014

Scientists uncover early steps of totipotency in sperm precursors

In the body, a skin cell will always be skin, and a heart cell will always be heart. But in the first hours of life, cells in the nascent embryo become totipotent: they have the incredible flexibility to mature into skin, heart, gut, or any type of cell.

20 May 2014

CTR1 may be required for successful platinum-based therapy in NSCLC

Tumours with undetectable levels of the copper transporter CTR1 have a significantly reduced response to platinum-based chemotherapy for non-small-cell lung cancer, study findings indicate.

19 May 2014

Vandetanib delays disease progression in elderly NSCLC patients

Vandetanib used in combination with gemcitabine significantly improves progression-free survival compared with gemcitabine alone when used as a first-line treatment for elderly patients with advanced non-small-cell lung cancer, Italian researchers report.

19 May 2014

SUVmax predicts outcome in advanced NSCLC

Parameters measured by positron emission tomography with integrated computed tomography at diagnosis can be used to predict outcome following concurrent chemoradiotherapy for stage III non-small-cell lung cancer, research shows.

19 May 2014

HRQoL changes predict survival in NSCLC

Changes in health-related quality of life during treatment may help predict survival in patients with advanced non-small-cell lung cancer, suggest findings from the EORTC 08975 study.

19 May 2014

Three scientists selected to receive NIDA's 2014 Avant-Garde Award for HIV/AIDS Research

With proposals ranging from enhancing the immune system's ability to fight HIV infection to improving long-term immune health in HIV-infected drug users, three scientists have been chosen to receive the 2014 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse, part of the National Institutes of Health.

19 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.

19 May 2014